Microbiotica has announced the appointment of Dr John Shields as a non-executive director representing the Sanger Institute.

Dr Shields has extensive operational and investment experience in the biotechnology sector and is currently a member of the Sanger Institute Translation Committee, the Crick Institute Translation Advisory Group and the Medical Research Council’s Translational Research Group. He serves on a number of biotechnology company boards and is an adviser to several venture capital groups. Previously, he was an adviser to Abingworth Management, the life-sciences focused venture capital group, and has also worked in the pharma and biotech industry, initially at Glaxo and then as SVP Research for Cantab Pharmaceuticals.  

Mike Romanos, Chief Executive Officer of Microbiotica, commented: “We are delighted to welcome John to Microbiotica’s Board. His experience in the translation of innovative science will bring invaluable insights to the company as we work to commercialise ground-breaking research into the role of the human microbiome in health and disease, and its application to medicine. His appointment is a welcome and tangible demonstration of our ongoing close link with the Sanger Institute, and I am sure he will make an immediate and important contribution to the team.”

Dr Shields commented: “Microbiotica is an immensely interesting organisation with, I believe, significant potential to apply its understanding of the role of human gut microbiome in health and disease to develop bacteriotherapies. I am looking forward to helping the team realise the enormous opportunity which is emerging from our increased knowledge of the role of the microbiome and to offering a new approach for treating diseases for which conventional treatments have been inadequate.”

Dr Shields joins existing Microbiotica Board members Mike Romanos, CEO, and Trevor Lawley, Chief Scientific Officer, along with Sam Williams, Head of Biotech at IP Group plc, and Robert Tansley, Investment Director at Cambridge Innovation Capital plc.